EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
Executive Summary
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.
You may also be interested in...
Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe
Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.
Volanesorsen, Inotersen And Erenumab Nearing End Of EU Review Process
Some 17 products are in the late stages of evaluation at the European Medicines Agency, including half a dozen orphans, a handful of other new drugs, and a clutch of biosimilars.
Volanesorsen, Inotersen And Erenumab Nearing End Of EU Review Process
Some 17 products are in the late stages of evaluation at the European Medicines Agency, including half a dozen orphans, a handful of other new drugs, and a clutch of biosimilars.